Pharmacopoeial impurityBis-(1,7-Dihydro-6H-Purine)-6,6-DisulfideCat. No. P-M061-002CAS 49808-20-0Family · Pharmaceutical analytical standards
Mercaptopurine
A thiopurine antimetabolite that blocks the synthesis of purine nucleotides; developed in 1950 by Gertrude Elion and George Hitchings and approved in the United States in 1953, it is used against acute lymphoblastic leukaemia and in inflammatory bowel disease. This family brings together pharmacopoeial impurities, labelled standards and other impurities.
Did you know?Gertrude Elion never completed her doctorate, as she gave up her evening studies to keep her laboratory job: in 1988 she nonetheless won the Nobel Prize in Medicine, with Hitchings and James Black.
Pharmacopoeial impurityBis-(1,7-Dihydro-6H-Purine)-6,6-DisulfideCat. No. P-M061-002CAS 49808-20-0
Isotopically labelled2-Amino-6-mercaptopurine-13C2,15NCat. No. P-M061-004CAS 1330266-29-9
Isotopically labelled6-Mercaptopurine-13C2-15NCat. No. P-M061-006CAS 1190008-04-8
Impurity6-MercaptopurineCat. No. P-M061-007CAS 50-44-2No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
ImpurityMercaptopurine impurity A CRSEDQM code Y0002147Family Mercaptopurine
ImpurityMercaptopurine impurity B CRSEDQM code Y0002148Family MercaptopurineImpurityMercaptopurine impurity D CRSEDQM code Y0002152Family Mercaptopurine
Reference substanceMercaptopurine monohydrate CRSEDQM code Y0002452Family MercaptopurineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.